Quick Answer
HeartSciences Inc. reported Research And Development Expense of $4.39 million for the year ending 2025.
- HeartSciences Inc. showed an increase of +52.4% in Research And Development Expense from 2024 to 2025.
- This data is from HeartSciences Inc.'s annual report (Form 10-K), filed with the SEC on July 24, 2025.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $401.1 thousand | Q4 2021: $545.8 thousand | Q1 2022: $699.0 thousand | Q3 2022: $434.2 thousand | Q4 2022: $849.0 thousand | Q1 2023: $643.3 thousand | Q3 2023: $565.6 thousand | Q4 2023: $757.3 thousand | Q1 2024: $509.5 thousand | Q3 2024: $1.22 million | Q4 2024: $1.20 million | Q1 2025: $1.03 million | Q3 2025: $997.2 thousand | Q4 2025: $727.0 thousand | Q1 2026: $638.6 thousand.
- Over the full 4 years of available data (2022 to 2025), HeartSciences Inc.'s Research And Development Expense has grown by 46.1%.
- Historical annual values: Fiscal year 2025: $4.39 million | Fiscal year 2024: $2.88 million | Fiscal year 2023: $2.46 million | Fiscal year 2022: $3.00 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: